GE Healthcare has received FDA approval for SenoClaire, a breast tomosynthesis solution using 3D imaging technology. Developed in partnership with Massachusetts General Hospital, the technology uses a low-dose short x-ray sweep around the breast to produce nine exposures, reducing image blur due to motion, and increasing sharpness. The technology is available for sale in the United States as an upgradeable feature on GE’s 2000 SenoGraphe Essential system.
“3D breast screening technology helps clinicians uncover small cancers which can be a limiting factor in standard 2D mammography. As a radiologist, it’s important to offer technology like this for patients that produces higher image quality without increasing dose,” said Murray Rebner MD, director of the division of breast imaging and intervention at Beaumont Hospital, Royal Oak. “We believe this technology can have a significant impact on helping clinicians to identify breast cancer.”
SenoClaire produces no additional radiation dose when switching from a standard 2D mammogram to a 3D view. The technology complements the Centricity PACS with Universal Viewer and is DICOM-compliant. When used with the Centricity PACS and Centricity Clinical Archive solution, the technology makes available a patient’s longitudinal record for improved care.
“Today’s announcement marks a key milestone in our mission of providing women with cutting edge screening technology to detect early breast cancer,” Daniel Kopans, senior radiologist for the breast imaging division department of radiology at Massachusetts General Hospital, said yesterday. “When cancer is identified and treated earlier, we know women have a better rate of survival.”
For more information, visit GE Healthcare.
